von Hippel-Lindau disease.

By R. Lonser, G. Glenn, McClellan Walther, Emily Y. Chew, S. Libutti, W. Marston Linehan, E. Oldfield. The Lancet, 2003

2,062 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/e140f0179be12f6f84a2e212ac13484c16be38be

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Kerbel
2. N. Ferrara
3. Rakesh K. Jain
4. A. Adamis
5. H. Gerber
6. M. Shibuya

In Pulmonary and Respiratory Medicine

1. N. Ferrara
2. R. Kerbel

Citations in the corpus

• The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer (2008, neutral): “Both HIF-dependent and HIF-independent VHL functions are likely to contribute to VHL-defective tumorigenesi”
• Angiogenesis as a therapeutic target (2005, positive): “Renal cell carcinomas have a particularly high level of VEGF-A expression, consistent with the notion that inactivating VHL mutations occur in about 50p of such tumour”
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, neutral): “The gene encoding VHL is inactivated in patients with von Hippel-Lindau disease, an autosomal dominant neoplasia syndrome characterized by capillary haemangioblastomas in retina and cerebellum, and in most sporadic clear-cell renal carcinoma”